share_log

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73

Canaccord Genuity維持對Intellia Therapeutics的買入，將目標股價上調至7
Benzinga ·  02/23 22:54

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $72 to $73.

Canaccord Genuity分析師惠特尼·伊傑姆維持Intellia Therapeutics（納斯達克股票代碼：NTLA）的買入並將目標股價從72美元上調至73美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論